|

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

RECRUITINGN/ASponsored by Deling Li
Actively Recruiting
PhaseN/A
SponsorDeling Li
Started2025-07-04
Est. completion2026-12-31
Eligibility
Age14 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07177482

Summary

This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.

Eligibility

Age: 14 Years – 80 YearsHealthy volunteers accepted
Inclusion criteria:

* must be able to provide a written informed consent
* radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
* adequate clinical condition (Karnofsky performance status ≥70)

Exclusion criteria:

* concomitant major central nervous system disorders
* severe hepatic or renal dysfunction
* history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
* claustrophobia precluding PET/CT or MRI examinations
* pregnancy or breastfeeding

Conditions2

CancerCraniopharyngioma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.